TAKANASHI KEN 4
4 · Satsuma Pharmaceuticals, Inc. · Filed Jun 16, 2020
Insider Transaction Report
Form 4
TAKANASHI KEN
Director10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2020-06-12+10,000→ 10,000 totalExercise: $26.99Exp: 2030-06-11→ Common Stock (10,000 underlying)
Holdings
- 1,561,719(indirect: See footnote)
Common Stock, $0.0001 par value
Footnotes (3)
- [F1]Shares are held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.
- [F2]The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.
- [F3]The option shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the first Annual Meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through the applicable vesting date.